The estimated Net Worth of Finckenstein Friedrich Graf is at least $3.63 Milion dollars as of 3 September 2024. Friedrich Graf owns over 27,345 units of Iovance Biotherapeutics Inc stock worth over $666,029 and over the last 5 years he sold IOVA stock worth over $0. In addition, he makes $2,963,950 as Chief Medical Officer at Iovance Biotherapeutics Inc.
Friedrich has made over 12 trades of the Iovance Biotherapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 27,345 units of IOVA stock worth $255,676 on 3 September 2024.
The largest trade he's ever made was exercising 27,345 units of Iovance Biotherapeutics Inc stock on 3 September 2024 worth over $255,676. On average, Friedrich trades about 6,020 units every 43 days since 2019. As of 3 September 2024 he still owns at least 71,233 units of Iovance Biotherapeutics Inc stock.
You can see the complete history of Friedrich Graf stock trades at the bottom of the page.
Dr. Friedrich Graf Finckenstein M.D. serves as Chief Medical Officer of the Company. Dr. Graf Finckenstein is a physician-scientist with decades of experience in clinical medicine, laboratory cancer research, and drug development in the biopharmaceutical industry. Prior to joining Iovance he was Global Head of Oncology Translational Medicine at Roche Pharma Research and Early Development (pRED) in Basel, Switzerland, where he led all clinical development aspects in the Oncology Discovery and Translational Area, including the design and conduct of clinical trials, exploratory development studies and translational medicine, biomarker and personalized healthcare strategy. Prior to that, Dr. Graf Finckenstein held multiple clinical leadership roles at Bristol-Meyers Squibb Company, where he worked on an array of products from early clinical development to late stage, including key contributions to the approval of Opdivo(R) in lung cancer. Dr. Graf Finckenstein has a medical degree from the University of Hamburg in Germany. He holds a German medical license, a pediatric board certification, and has conducted basic cancer research at the Ludwig Institute, San Diego Branch, the Children's Hospital Los Angeles and the University of Hamburg.
As the Chief Medical Officer of Iovance Biotherapeutics Inc, the total compensation of Friedrich Finckenstein at Iovance Biotherapeutics Inc is $2,963,950. There are 1 executives at Iovance Biotherapeutics Inc getting paid more, with Maria Fardis having the highest compensation of $4,107,960.
Friedrich Finckenstein is 53, he's been the Chief Medical Officer of Iovance Biotherapeutics Inc since 2019. There are 6 older and 8 younger executives at Iovance Biotherapeutics Inc. The oldest executive at Iovance Biotherapeutics Inc is Merrill McPeak, 84, who is the Independent Director.
Finckenstein's mailing address filed with the SEC is C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070.
Over the last 8 years, insiders at Iovance Biotherapeutics Inc have traded over $0 worth of Iovance Biotherapeutics Inc stock and bought 22,614,553 units worth $159,655,586 . The most active insiders traders include Wayne P. Rothbaum, Merrill A Mcpeak oraz Timothy E Morris. On average, Iovance Biotherapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $3,815,146. The most recent stock trade was executed by Frederick G Vogt on 3 September 2024, trading 57,292 units of IOVA stock currently worth $535,680.
iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical
Iovance Biotherapeutics Inc executives and other stock owners filed with the SEC include: